Polylite Taiwan Co., Ltd.

TPEX:1813 Stock Report

Market Cap: NT$909.4m

Polylite Taiwan Valuation

Is 1813 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1813 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1813 (NT$19.5) is trading above our estimate of fair value (NT$9.39)

Significantly Below Fair Value: 1813 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1813?

Key metric: As 1813 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1813. This is calculated by dividing 1813's market cap by their current revenue.
What is 1813's PS Ratio?
PS Ratio2.8x
SalesNT$320.03m
Market CapNT$909.39m

Price to Sales Ratio vs Peers

How does 1813's PS Ratio compare to its peers?

The above table shows the PS ratio for 1813 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.7x
6543 Perfect Medical Industry
1.8xn/aNT$1.4b
4183 EPS Bio Technology
1.1xn/aNT$541.5m
3373 Radiant Innovation
2.4xn/aNT$961.0m
6649 Taiwan Biomaterial
17.7xn/aNT$1.5b
1813 Polylite Taiwan
2.8xn/aNT$909.4m

Price-To-Sales vs Peers: 1813 is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (5.7x).

Price to Sales Ratio vs Industry

How does 1813's PS Ratio compare vs other companies in the TW Medical Equipment Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
4116 BenQ Medical Technology
0.5xn/aUS$65.32m
4121 Rossmax International
0.4xn/aUS$45.23m
No more companies available in this PS range
1813 2.8xIndustry Avg. 2.8xNo. of Companies10PS02.44.87.29.612+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1813 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the TW Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is 1813's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1813 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1813's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.3b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$215.50

7D

1.9%

1Y

-27.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

7D

0.4%

1Y

2.6%

Pacific Hospital Supply

NT$6.5b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$89.00

7D

-0.3%

1Y

6.0%